Safety and Efficacy of Triple Therapy with Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors in Treatment-Naive Human Immunodeficiency Virus Type 2 Patients: Results from a 48-Week Phase 2 Study.
Clinical infectious diseases/Clinical infectious diseases (Online University of Chicago Press)（2023）
关键词
antiretroviral treatment,HIV-2,integrase inhibitor,dolutegravir
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要